Skip to main content

Advertisement

SpringerLink
Log in

Surgical Considerations in Advance Basal Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, and Cutaneous Melanoma: a Head and Neck Perspective

  • HEAD & NECK: Non-melanoma Skin Cancer of the Head and Neck (J Moyer, Section Editor)
  • Published:
Current Otorhinolaryngology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Skin cancers, including basal cell carcinoma, cutaneous squamous cell carcinoma, and cutaneous melanoma, are the most common cancer worldwide. The treatment of these cancers is primarily surgical, and when treated early and correctly, the prognosis is excellent. In this review, we aim to discuss the appropriate surgical management of skin cancers and associated controversies as it pertains to the head and neck.

Recent Findings

Evidences guiding treatment have expanded enormously over the past decade. Studies have drastically improved our understanding of skin cancer including risk factors for tumor recurrence and metastasis, indicated margin size of surgical excision, the role of sentinel lymph node biopsy, and the management of occult and gross regional neck metastasis.

Summary

Management of skin cancer poses a unique challenge in the head and neck region due to its proximity to anatomic sensitive areas and complex lymphatic drainage. Understanding how to efficiently manage the primary tumor site and the regional lymph nodes is paramount in minimizing locoregional recurrence and improving overall survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin Cancer (keratinocyte carcinomas) in the U.S. population, 2012. JAMA Dermatol. 2015;151:1081–6.

    Article  PubMed  Google Scholar 

  2. Gloster HM, Neal K. Skin cancer in skin of color. J Am Acad Dermatol. 2006;55:741–60.

    Article  PubMed  Google Scholar 

  3. Staples M, Marks R, Giles G. Trends in the incidence of non-melanocytic skin cancer (NMSC) treated in Australia 1985-1995: are primary prevention programs starting to have an effect? Int J Cancer. 1998;78:144–8.

    Article  PubMed  CAS  Google Scholar 

  4. Nestor MS, Zarraga MB. The incidence of nonmelanoma skin cancers and actinic keratoses in South Florida. J Clin Aesthetic Dermatol. 2012;5:20–4.

    Google Scholar 

  5. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Melanoma of the Skin [Internet]. National Cancer Institute; [cited 2018 Jan 30]. Available from: https://seer.cancer.gov/statfacts/html/melan.html

  6. American Cancer Society. Cancer Facts & Figures 2018 [Internet]. American Cancer Society; [cited 2018 Jan 30]. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf

  7. Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol. 1994;30:774–8.

    Article  PubMed  CAS  Google Scholar 

  8. Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med. 2005;353:2262–9.

    Article  PubMed  CAS  Google Scholar 

  9. McCusker M, Basset-Seguin N, Dummer R, Lewis K, Schadendorf D, Sekulic A, et al. Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease. Eur J Cancer. 2014;50:774–83.

  10. •• National Comprehensive Cancer Network. Basal cell skin cancer (version 1.2018) [Internet]. NCCN Clnical Practice Guidelines in Oncology; [cited 2018 Jan 30]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf. National Comprehensive Cancer Network guidelines on management of basal cell carcinoma.

  11. Gooding CA, White G, Yatsuhashi M. Significance of marginal extension in excised basal-cell carcinoma. N Engl J Med. 1965;273:923–4.

    Article  PubMed  CAS  Google Scholar 

  12. Liu FF, Maki E, Warde P, Payne D, Fitzpatrick P. A management approach to incompletely excised basal cell carcinomas of skin. Int J Radiat Oncol Biol Phys. 1991;20:423–8.

    Article  PubMed  CAS  Google Scholar 

  13. Codazzi D, Van Der Velden J, Carminati M, Bruschi S, Bocchiotti MA, Di Serio C, et al. Positive compared with negative margins in a single-centre retrospective study on 3957 consecutive excisions of basal cell carcinomas. Associated risk factors and preferred surgical management. J Plast Surg Hand Surg. 2014;48:38–43.

    Article  PubMed  CAS  Google Scholar 

  14. Kumar P, Orton CI, McWilliam LJ, Watson S. Incidence of incomplete excision in surgically treated basal cell carcinoma: a retrospective clinical audit. Br J Plast Surg. 2000;53:563–6.

    Article  PubMed  CAS  Google Scholar 

  15. Rieger KE, Linos E, Egbert BM, Swetter SM. Recurrence rates associated with incompletely excised low-risk nonmelanoma skin cancer. J Cutan Pathol. 2010;37:59–67.

    Article  PubMed  Google Scholar 

  16. Pascal RR, Hobby LW, Lattes R, Crikelair GF. Prognosis of “incompletely excised” versus “completely excised” basal cell carcinoma. Plast Reconstr Surg. 1968;41:328–32.

    Article  PubMed  CAS  Google Scholar 

  17. Masud D, Moustaki M, Staruch R, Dheansa B. Basal cell carcinomata: risk factors for incomplete excision and results of re-excision. J Plast Reconstr Aesthet Surg. 2016;69:652–6.

    Article  PubMed  CAS  Google Scholar 

  18. Wolf DJ, Zitelli JA. Surgical margins for basal cell carcinoma. Arch Dermatol. 1987;123:340–4.

    Article  PubMed  CAS  Google Scholar 

  19. •• Bichakjian C, Armstrong A, Baum C, Bordeaux JS, Brown M, Busam KJ, et al. Guidelines of care for the management of basal cell carcinoma. J Am Acad Dermatol. 2018;S0190–9622:32529–X. Guidelines by the American Academy of Dermatology on the management of basal cell carcinoma

    Google Scholar 

  20. •• Porceddu SV, Veness MJ, Guminski A. Nonmelanoma cutaneous head and neck cancer and Merkel cell carcinoma: current concepts, advances, and controversies. J Clin Oncol. 2015;33:3338–45. Latest recommendations by the American Society of Clinical Oncology on management of basal cell carcinoma and cutaneous squamous cell carcinoma

    Article  PubMed  CAS  Google Scholar 

  21. van Loo E, Mosterd K, Krekels GAM, Roozeboom MH, Ostertag JU, Dirksen CD, et al. Surgical excision versus Mohs’ micrographic surgery for basal cell carcinoma of the face: a randomised clinical trial with 10 year follow-up. Eur J Cancer. 2014;50:3011–20.

  22. Thissen MR, Neumann MH, Schouten LJ. A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol. 1999;135:1177–83.

    Article  PubMed  CAS  Google Scholar 

  23. Rowe DE, Carroll RJ, Day CL. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol. 1989;15:315–28.

    Article  PubMed  CAS  Google Scholar 

  24. Tierney EP, Hanke CW. Cost effectiveness of Mohs micrographic surgery: review of the literature. J Drugs Dermatol. 2009;8:914–22.

    PubMed  Google Scholar 

  25. Muller FM, Dawe RS, Moseley H, Fleming CJ. Randomized comparison of Mohs micrographic surgery and surgical excision for small nodular basal cell carcinoma: tissue-sparing outcome. Dermatol Surg. 2009;35:1349–54.

    Article  PubMed  CAS  Google Scholar 

  26. Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med. 2001;344:975–83.

    Article  PubMed  CAS  Google Scholar 

  27. Karia PS, Han J, Schmults CD. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol. 2013;68:957–66.

    Article  PubMed  Google Scholar 

  28. Johnson TM, Rowe DE, Nelson BR, Swanson NA. Squamous cell carcinoma of the skin (excluding lip and oral mucosa). J Am Acad Dermatol. 1992;26:467–84.

    Article  PubMed  CAS  Google Scholar 

  29. Tseros EA, Gebski V, Morgan GJ, Veness MJ. Prognostic significance of lymph node ratio in metastatic cutaneous squamous cell carcinoma of the head and neck. Ann Surg Oncol. 2016;23:1693–8.

    Article  PubMed  Google Scholar 

  30. Manyam BV, Garsa AA, Chin R-I, Reddy CA, Gastman B, Thorstad W, et al. A multi-institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck. Cancer. 2017;123:2054–60.

  31. Karia PS, Jambusaria-Pahlajani A, Harrington DP, Murphy GF, Qureshi AA, Schmults CD. Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women’s Hospital tumor staging for cutaneous squamous cell carcinoma. J Clin Oncol. 2014;32:327–34.

    Article  PubMed  Google Scholar 

  32. • Motaparthi K, Kapil JP, Velazquez EF. Cutaneous squamous cell carcinoma: review of the eighth edition of the American Joint Committee on Cancer staging guidelines, prognostic factors, and histopathologic variants. Adv Anat Pathol. 2017;24:171–94. A review of changes in the American Joint Committee on Cancer Staging 8th edition in staging cutaneous squamous cell carcinoma. It also reviews clinical and pathologic prognostic factors

    Article  PubMed  Google Scholar 

  33. •• National Comprehensive Cancer Network. Squamous cell skin cancer (version 2.2018) [Internet]. NCCN Clnical Practice Guidelines in Oncology; [cited 2018 Jan 30]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf. National Comprehensive Cancer Network guidelines on management of cutaneous squamous cell carcinoma.

  34. Cassarino DS, Derienzo DP, Barr RJ. Cutaneous squamous cell carcinoma: a comprehensive clinicopathologic classification: part one. J Cutan Pathol. 2006;33:191–206.

    PubMed  Google Scholar 

  35. Cassarino DS, Derienzo DP, Barr RJ. Cutaneous squamous cell carcinoma: a comprehensive clinicopathologic classification: part two. J Cutan Pathol. 2006;33:261–79.

    Article  PubMed  Google Scholar 

  36. Velazquez EF, Werchniack AE, Granter SR. Desmoplastic/spindle cell squamous cell carcinoma of the skin. A diagnostically challenging tumor mimicking a scar: clinicopathologic and immunohistochemical study of 6 cases. Am J Dermatopathol. 2010;32:333–9.

    Article  PubMed  Google Scholar 

  37. Rizvi SMH, Aagnes B, Holdaas H, Gude E, Boberg KM, Bjørtuft Ø, et al. Long-term change in the risk of skin Cancer after organ transplantation: a population-based Nationwide cohort study. JAMA Dermatol. 2017;153:1270–7.

  38. •• Alam M, Armstrong A, Baum C, Bordeaux JS, Brown M, Busam KJ, et al. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2018;S0190–9622:32530–6. Guidelines by the American Academy of Dermatology on the management of cutaneous squamous cell carcinoma

    Google Scholar 

  39. Brodland DG, Zitelli JA. Surgical margins for excision of primary cutaneous squamous cell carcinoma. J Am Acad Dermatol. 1992;27:241–8.

    Article  PubMed  CAS  Google Scholar 

  40. Schell AE, Russell MA, Park SS. Suggested excisional margins for cutaneous malignant lesions based on Mohs micrographic surgery. JAMA Facial Plast Surg. 2013;15:337–43.

    Article  PubMed  Google Scholar 

  41. Rowe DE, Carroll RJ, Day CL. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol. 1992;26:976–90.

    Article  PubMed  CAS  Google Scholar 

  42. Leibovitch I, Huilgol SC, Selva D, Hill D, Richards S, Paver R. Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia I. Experience over 10 years. J Am Acad Dermatol. 2005;53:253–60.

    Article  PubMed  Google Scholar 

  43. Gore SM, Shaw D, Martin RCW, Kelder W, Roth K, Uren R, et al. Prospective study of sentinel node biopsy for high-risk cutaneous squamous cell carcinoma of the head and neck. Head Neck. 2016;38(Suppl 1):E884–9.

  44. Durham AB, Lowe L, Malloy KM, McHugh JB, Bradford CR, Chubb H, et al. Sentinel lymph node biopsy for cutaneous squamous cell carcinoma on the head and neck. JAMA Otolaryngol Head Neck Surg. 2016;142:1171–6.

    Article  PubMed  Google Scholar 

  45. Schmitt AR, Brewer JD, Bordeaux JS, Baum CL. Staging for cutaneous squamous cell carcinoma as a predictor of sentinel lymph node biopsy results: meta-analysis of American joint committee on Cancer criteria and a proposed alternative system. JAMA Dermatol. 2014;150:19–24.

    Article  PubMed  Google Scholar 

  46. Ahadiat O, Higgins S, Sutton A, Ly A, Wysong A. SLNB in cutaneous SCC: a review of the current state of literature and the direction for the future. J Surg Oncol. 2017;116:344–50.

    Article  PubMed  Google Scholar 

  47. Cannon RB, Dundar Y, Thomas A, Monroe MM, Buchmann LO, Witt BL, et al. Elective neck dissection for head and neck cutaneous squamous cell carcinoma with skull base invasion. Otolaryngol Head Neck Surg. 2017;156:671–6.

  48. Czerwonka L, De Santis RJ, Horowitz G, Hong M, Orsini M, Enepekides D, et al. Staging cutaneous squamous cell carcinoma metastases to the parotid gland. Laryngoscope. 2017;127:2063–9.

    Article  PubMed  Google Scholar 

  49. Andruchow JL, Veness MJ, Morgan GJ, Gao K, Clifford A, Shannon KF, et al. Implications for clinical staging of metastatic cutaneous squamous carcinoma of the head and neck based on a multicenter study of treatment outcomes. Cancer. 2006;106:1078–83.

  50. O’Brien CJ, McNeil EB, McMahon JD, Pathak I, Lauer CS. Incidence of cervical node involvement in metastatic cutaneous malignancy involving the parotid gland. Head Neck. 2001;23:744–8.

    Article  PubMed  Google Scholar 

  51. Balch CM, Gershenwald JE, Soong S-J, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199–206.

  52. Lachiewicz AM, Berwick M, Wiggins CL, Thomas NE. Survival differences between patients with scalp or neck melanoma and those with melanoma of other sites in the Surveillance, Epidemiology, and End Results (SEER) program. Arch Dermatol. 2008;144:515–21.

    Article  PubMed  Google Scholar 

  53. Breslow A, Macht SD. Optimal size of resection margin for thin cutaneous melanoma. Surg Gynecol Obstet. 1977;145:691–2.

    PubMed  CAS  Google Scholar 

  54. Veronesi U, Cascinelli N, Adamus J, Balch C, Bandiera D, Barchuk A, et al. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med. 1988;318:1159–62.

  55. Cohn-Cedermark G, Rutqvist LE, Andersson R, Breivald M, Ingvar C, Johansson H, et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer. 2000;89:1495–501.

  56. Balch CM, Soong SJ, Smith T, Ross MI, Urist MM, Karakousis CP, et al. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol. 2001;8:101–8.

  57. Khayat D, Rixe O, Martin G, Soubrane C, Banzet M, Bazex J-A, et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer. 2003;97:1941–6.

  58. Thomas JM, Newton-Bishop J, A’Hern R, Coombes G, Timmons M, Evans J, et al. Excision margins in high-risk malignant melanoma. N Engl J Med. 2004;350:757–66.

    Article  PubMed  CAS  Google Scholar 

  59. Gillgren P, Drzewiecki KT, Niin M, Gullestad HP, Hellborg H, Månsson-Brahme E, et al. 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial. Lancet. 2011;378:1635–42.

  60. •• National Comprehensive Cancer Network. Melanoma (version 2.2018) [Internet]. NCCN Clnical Practice Guidelines in Oncology; [cited 2018 Jan 30]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf. National Comprehensive Cancer Network guidelines on management of cutaneous melanoma.

  61. • Bichakjian CK, Halpern AC, Johnson TM, Foote Hood A, Grichnik JM, Swetter SM, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2011;65:1032–47. Guidelines published in 2011 by the American Academy of Dermatology on the management of basal cell carcinoma. Updated guidelines are anticipated in summer of 2018

  62. Veronesi U, Adamus J, Bandiera DC, Brennhovd O, Caceres E, Cascinelli N, et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer. 1982;49:2420–30.

    Article  PubMed  CAS  Google Scholar 

  63. Sim FH, Taylor WF, Pritchard DJ, Soule EH. Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc. 1986;61:697–705.

    Article  PubMed  CAS  Google Scholar 

  64. Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO melanoma Programme. Lancet. 1998;351:793–6.

    Article  PubMed  CAS  Google Scholar 

  65. Balch CM, Soong S, Ross MI, Urist MM, Karakousis CP, Temple WJ, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol. 2000;7:87–97.

  66. Eicher SA, Clayman GL, Myers JN, Gillenwater AM. A prospective study of intraoperative lymphatic mapping for head and neck cutaneous melanoma. Arch Otolaryngol Head Neck Surg. 2002;128:241–6.

    Article  PubMed  Google Scholar 

  67. Erman AB, Collar RM, Griffith KA, Lowe L, Sabel MS, Bichakjian CK, et al. Sentinel lymph node biopsy is accurate and prognostic in head and neck melanoma. Cancer. 2012;118:1040–7.

  68. Han D, Yu D, Zhao X, Marzban SS, Messina JL, Gonzalez RJ, et al. Sentinel node biopsy is indicated for thin melanomas ≥0.76 mm. Ann Surg Oncol. 2012;19:3335–42.

  69. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622–34.

  70. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, Roses DF, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370:599–609.

  71. Kachare SD, Singla P, Vohra NA, Zervos EE, Wong JH, Fitzgerald TL. Sentinel lymph node biopsy is prognostic but not therapeutic for thick melanoma. Surgery. 2015;158:662–8.

    Article  PubMed  Google Scholar 

  72. Ribero S, Osella-Abate S, Sanlorenzo M, Balagna E, Senetta R, Fierro MT, et al. Sentinel lymph node biopsy in thick-melanoma patients (N=350): what is its prognostic role? Ann Surg Oncol. 2015;22:1967–73.

  73. Sperry SM, Charlton ME, Pagedar NA. Association of sentinel lymph node biopsy with survival for head and neck melanoma: survival analysis using the SEER database. JAMA Otolaryngol-- Head Neck Surg. 2014;140:1101–9.

    Article  PubMed  PubMed Central  Google Scholar 

  74. van der Ploeg APT, Haydu LE, Spillane AJ, Quinn MJ, Saw RP, Shannon KF, et al. Outcome following sentinel node biopsy plus wide local excision versus wide local excision only for primary cutaneous melanoma: analysis of 5840 patients treated at a single institution. Ann Surg. 2014;260:149–57.

    Article  PubMed  Google Scholar 

  75. Kachare SD, Brinkley J, Wong JH, Vohra NA, Zervos EE, Fitzgerald TL. The influence of sentinel lymph node biopsy on survival for intermediate-thickness melanoma. Ann Surg Oncol. 2014;21:3377–85.

    Article  PubMed  Google Scholar 

  76. Morton DL, Cochran AJ, Thompson JF, Elashoff R, Essner R, Glass EC, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg. 2005;242:302–11. discussion 311-313

    PubMed  PubMed Central  Google Scholar 

  77. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng CH, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17:976–83.

  78. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307–17.

  79. Fadaki N, Li R, Parrett B, Sanders G, Thummala S, Martineau L, et al. Is head and neck melanoma different from trunk and extremity melanomas with respect to sentinel lymph node status and clinical outcome? Ann Surg Oncol. 2013;20:3089–97.

  80. Yalamanchi P, Brant JA, Chen J, Newman JG. Clinicopathologic factors predictive of occult lymph node involvement in cutaneous head and neck melanoma. Otolaryngol Head Neck Surg. 2017;194599817741641.

  81. Andtbacka RHI, Gershenwald JE. Role of sentinel lymph node biopsy in patients with thin melanoma. J Natl Compr Cancer Netw. 2009;7:308–17.

    Article  Google Scholar 

  82. Cordeiro E, Gervais M-K, Shah PS, Look Hong NJ, Wright FC. Sentinel lymph node biopsy in thin cutaneous melanoma: a systematic review and meta-analysis. Ann Surg Oncol. 2016;23:4178–88.

    Article  PubMed  Google Scholar 

  83. Han D, Zager JS, Shyr Y, Chen H, Berry LD, Iyengar S, et al. Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. J Clin Oncol. 2013;31:4387–93.

  84. Murali R, Haydu LE, Quinn MJ, Saw RPM, Shannon K, Spillane AJ, et al. Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma. Ann Surg. 2012;255:128–33.

  85. Kirkland EB, Zitelli JA. Mitotic rate for thin melanomas: should a single mitotic figure warrant a sentinel lymph node biopsy? Dermatol Surg. 2014;40:937–45.

    Article  PubMed  CAS  Google Scholar 

  86. Bartlett EK, Peters MG, Blair A, Etherington MS, Elder DE, Xu XG, et al. Identification of patients with intermediate thickness melanoma at low risk for sentinel lymph node positivity. Ann Surg Oncol. 2016;23:250–6.

  87. •• Wong SL, Faries MB, Kennedy EB, Agarwala SS, Akhurst TJ, Ariyan C, et al. Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American Society of Clinical Oncology and Society of Surgical Oncology clinical practice guideline update. J Clin Oncol. 2017;36:399–413. Latest recommendations by the American Society of Clinical Oncology on the role of sentinel lymph node biopsy and completion lymph node dissection in melanoma

    Article  PubMed  Google Scholar 

  88. Pathak I, O’Brien CJ, Petersen-Schaeffer K, McNeil EB, McMahon J, Quinn MJ, et al. Do nodal metastases from cutaneous melanoma of the head and neck follow a clinically predictable pattern? Head Neck. 2001;23:785–90.

    Article  PubMed  CAS  Google Scholar 

  89. Thom JJ, Moore EJ, Price DL, Kasperbauer JL, Starkman SJ, Olsen KD. The role of total parotidectomy for metastatic cutaneous squamous cell carcinoma and malignant melanoma. JAMA Otolaryngol Head Neck Surg. 2014;140:548–54.

    Article  PubMed  Google Scholar 

  90. Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer N, Berking C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17:757–67.

  91. • Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376:2211–22. Prospective, randomized controlled trial investigating outcomes in patients with sentinel node metastasis who undergo completion lymph node dissection versus observation. Also known as the Multicenter Selective Lymphadenectomy Trial-II (MSLT-II)

  92. Pasquali S, Mocellin S, Mozzillo N, Maurichi A, Quaglino P, Borgognoni L, et al. Nonsentinel lymph node status in patients with cutaneous melanoma: results from a multi-institution prognostic study. J Clin Oncol. 2014;32:935–41.

  93. Roka F, Mastan P, Binder M, Okamoto I, Mittlboeck M, Horvat R, et al. Prediction of non-sentinel node status and outcome in sentinel node-positive melanoma patients. Eur J Surg Oncol. 2008;34:82–8.

  94. Leung AM, Morton DL, Ozao-Choy J, Hari DM, Shin-Sim M, Difronzo AL, et al. Staging of regional lymph nodes in melanoma: a case for including nonsentinel lymph node positivity in the American Joint Committee on Cancer staging system. JAMA Surg. 2013;148:879–84.

  95. Brown RE, Ross MI, Edwards MJ, Noyes RD, Reintgen DS, Hagendoorn LJ, et al. The prognostic significance of nonsentinel lymph node metastasis in melanoma. Ann Surg Oncol. 2010;17:3330–5.

  96. Moore BA, Weber RS, Prieto V, El-Naggar A, Holsinger FC, Zhou X, et al. Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck. Laryngoscope. 2005;115:1561–7.

    Article  PubMed  Google Scholar 

  97. Robinson JK. Sun exposure, sun protection, and vitamin D. JAMA. 2005;294:1541–3.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Otolaryngology – Head and Neck Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA

    Tom C. Zhou, Matthew O. Old & Stephen Y. Kang

  2. Department of Otolaryngology – Head and Neck Surgery, University of Toronto, Toronto, Ontario, Canada

    Antoine E. Eskander

  3. Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH, USA

    Matthew O. Old & Stephen Y. Kang

  4. Department of Otolaryngology – Head and Neck Surgery, University Hospitals Cleveland Medical Center, 11100 Euclid Avenue, Lakeside 1071, Cleveland, OH, 44106, USA

    Theodoros N. Teknos

  5. Comprehensive Cancer Center, University Hospitals Seidman Cancer Center, Cleveland, OH, USA

    Theodoros N. Teknos

Authors
  1. Tom C. Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antoine E. Eskander
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matthew O. Old
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stephen Y. Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Theodoros N. Teknos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Theodoros N. Teknos.

Ethics declarations

Conflict of Interest

The authors declare that they have no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the topical collection on HEAD and NECK: Non-melanoma Skin Cancer of the Head and Neck

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhou, T.C., Eskander, A.E., Old, M.O. et al. Surgical Considerations in Advance Basal Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, and Cutaneous Melanoma: a Head and Neck Perspective. Curr Otorhinolaryngol Rep 6, 140–150 (2018). https://doi.org/10.1007/s40136-018-0195-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40136-018-0195-3

Keywords

Search

Navigation